ECM2024, 17-19 June 2024, Copenhagen, Denmark400 participants from 20 countries; 200 abstracts; 40 speakers – all with one goal: improving our understanding of the ECM across fibro-inflammatory diseases. Researchers, medical doctors, and industry experts from different disease joined forces to learn from each other and discuss how to modulate the ECM to benefit patients.
Testimonials
ECM2022 in beautiful Copenhagen delivered new science, new ideas, and networking that led to new colleagues and collaborators. ECM2024 will undoubtedly build on the foundation of 2022, presenting new data, both clinical and pre-clinical, that support the role of the ECM in health and disease; moreover, I expect ECM2024 will add to the growing body of evidence that the ECM is a largely untapped pharmacological target across various organ systems. I’m very much looking forward to being back in Copenhagen!
Eric S. White, Clinical Program Lead, Boehringer Ingelheim Pharmaceuticals Inc., USA.
The ECM Pharmacology Congress is a unique gathering in an excellent venue where the top experts in the field shared their latest findings in an open atmosphere with topics covering both basic and clinical science.
David Gordon, Vice President, Cardiovascular and Fibrosis Discovery Biology, Bristol-Myers Squibb, Lawrenceville, New Jersey, USA.
ECM2022 has truly been an ECM knowledge party! Having in the same room all top experts in ECM pharmacology who were coming from different angles to solve the same problem, allowed for very creative discussions and brainstorming. Eliminating the disease-specific barriers allowed for cross-contamination of ideas, from oncology to fibrosis in many different organs, from proteomics, genomic, and transcriptomic datasets to systems for preclinical and translational research. I personally gained a broad insight into what other disease areas than mine look into when they talk about the ECM involvement in the different diseases, and what the challenges and opportunities for pharmacological development are.
Federica Genovese, Director of Cardiovascular and Renal Research, Nordic Bioscience, Denmark.
The biggest strength of ECM2022 was the clear focus on ECM, which allowed presenters to go more in depth with their ECM related research compared to other conferences, where ECM research is often seen as a minor area. This enabled the presenters to show a bigger picture of ECM involvement across diseases and led to great scientific discussions.
Rasmus Sund Pedersen, PhD Student, Department of Biomedical Sciences, University of Copenhagen, Denmark.
As a future medical doctor with a research interest in the ECM aspects of cardiovascular disease, ECM2022 offered everything I could have hoped for. The focus on ECM as a pharmacological target connected pre-clinical research to clinical research, emphasizing how novel ECM findings could eventually benefit patients, which I believe is of utmost importance. The congress covered ECM aspects in various disease states, allowing me to stay updated on the latest cardiovascular disease research while also gaining new research ideas from other conditions, such as cancer and lung disease. Lastly, being a medical- and early PhD student at that time, it was a lot of fun to present a poster and engage in discussions with like-minded participants about my work and theirs.”
Filip Hammaréus, Intern Physician, Ryhov County Hospital, Jönköping, Sweden and PhD student, Department of Health Medicine and Caring Sciences, Linköping University, Sweden.
